Alle verbonden artikelen

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Auteurs : Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, + collaborators (among others :, Dal Lago L, de Azambuja E, Dabakuyo-Yonli TS
Jaar : 2015
Journal : Ann Oncol
Volume : 26(5)
Pagina's : 873-879.

Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.

Auteurs : Ignatiadis M, Lee M, Jeffrey SS
Jaar : 2015
Journal : Clin Cancer Res
Volume : 21
Pagina's : 4786-800

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

Auteurs : Salgado R, Denkert C, Campbell C, Savas P, Nucifero P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart M, Michiels S, Bradbury I, Sotiriou C, Loi S
Jaar : 2015
Journal : JAMA Oncol
Volume : 1(4)
Pagina's : 448-54

Adult onset asynchronous multifocal eosinophilic granuloma of bone: an 11-year follow-up.

Auteurs : Dallaudière B, Kerger J, Malghem J, Galant C, Lecouvet FE
Jaar : 2015
Journal : Acta Radiol Open
Volume : 4(2)
Pagina's : 2047981614552217

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Auteurs : Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F, Brown D, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart-Gebhart M, Abramowicz M, Campbell PJ, Sotiriou C, Detours V
Jaar : 2015
Journal : Cell Rep
Volume : 13
Pagina's : 277-89

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Auteurs : Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A
Jaar : 2015
Journal : Breast Cancer Res. Treat.
Volume : 149(1)
Pagina's : 313

Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma.

Auteurs : Bouazza F, Poncelet A, Garcia CA, Delatte P, Engelholm JL, Gomez Galdon M, Deleporte A, Hendlisz A, Vanderlinden B, Flamen P, Donckier V
Jaar : 2015
Journal : World J Gastroenterol
Volume : 21
Pagina's : 9666-70

Evolving paradigms in multifocal breast cancer.

Auteurs : Salgado R, Aftimos P, Sotiriou C, Desmedt C
Jaar : 2015
Journal : Semin. Cancer Biol.
Volume : 31C
Pagina's : 111-118

Adjuvant systemic therapy in breast cancer: quo vadis?

Auteurs : Sonnenblick A, Piccart-Gebhart M
Jaar : 2015
Journal : Ann Oncol
Volume : 26(8)
Pagina's : 1629-34

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.

Auteurs : Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart M, Scaltriti M, Baselga J
Jaar : 2015
Journal : Ann Oncol
Volume : 26
Pagina's : 1494-500

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

Auteurs : Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair O, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber Rd, Godhirsch A, Korde L, Azim HA, Partridge AH
Jaar : 2015
Journal : Breast
Volume : 24(3)
Pagina's : 201-7

Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.

Auteurs : de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Hernández SB, Shih-Li C, Delhaye F, Focan C, Cornez N, Vindevoghel A, Beauduin M, Lemort M, Paesmans M, Suter T, Piccart-Gebhart M
Jaar : 2015
Journal : Eur J Cancer
Volume : 51
Pagina's : 2517-24

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).

Auteurs : Popescu RA, Schäfer R, Califano R, Eckert R, Coleman R, Douillard JY, Cervantes A, Casali PG, Sessa C, van Cutsem E, De Vries E, Pavlidis N, Fumasoli K, Wörmann B, Samonigg H, Cascinu S, Cruz Hernández JJ, Howard AJ, Ciardiello F, Stahel RA, Piccart-Gebhart M
Jaar : 2014
Journal : Ann Oncol
Volume : 25(1)
Pagina's : 9-15

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

Auteurs : Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart-Gebhart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA
Jaar : 2014
Journal : Ann Oncol
Volume : 25(4)
Pagina's : 808-15

Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives.

Auteurs : Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart-Gebhart M
Jaar : 2014
Journal : J. Clin. Oncol.
Volume : 32(25)
Pagina's : 2794-803

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

Auteurs : Bonnefoi H, Litière S, Piccart-Gebhart M, Macgrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmström P, Werutsky G, Bogaerts J, Bergh J, Cameron DA
Jaar : 2014
Journal : Ann Oncol
Volume : 25(6)
Pagina's : 1128-36

A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).

Auteurs : Fumoleau P, Koch KM, Brain E, Lokiec F, Rezai K, Awada A, Hayward L, Werutsky G, Bogaerts J, Marréaud S, Cardoso F
Jaar : 2014
Journal : Breast
Volume : 23(5)
Pagina's : 663-9

A rare case of prostatic extra gonadal germ cell tumor in a young adult: Review of the literature

Auteurs : Sideris S, Aftimos P, Georgala A, Sirtaine N, Awada A, Gil T
Jaar : 2014
Journal : J Clin Diagn Res
Volume : 2
Pagina's : 2

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Auteurs : Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart-Gebhart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, Pazdur R, Ditsch N, Rastogi P, Eiermann W, Von Minckwitz G
Jaar : 2014
Journal : Lancet
Volume : 384(9938)
Pagina's : 164-72

The Role of Age on Dose Limiting Toxicities (DLTs) in Phase I Dose-escalation Trials.

Auteurs : Schwandt A, Harris PJ, Hunsberger S, Deleporte A, Smith GL, Vulih D, Anderson BD, Ivy SP
Jaar : 2014
Journal : Clin Cancer Res
Volume : 20(18)
Pagina's : 4768-75